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La´szlo´ Somsa´k
Department of Organic Chemistry, University of Debrecen, POB 20, 4010 Debrecen, Hungary
1. Introduction
One of the major aims of chemical biology [1], the
young and developing scientiﬁc ﬁeld between chemistry
and biology, is to ﬁnd matches between the biological and
chemical space [2]. The chemical space comprises (small)
molecules, some of which show complementary features
to certain points of the biological space constituted by the
structure of binding sites of biomacromolecules (mainly
but not only proteins). Good matches may result in
efﬁcient agonists/antagonists of receptors or activators/
inhibitors of enzymes. Such interactions contribute to the
basic understanding of the way of biological action of the
macromolecule, and may ultimately be utilised in drug
design and discovery.
In the context of this survey, the biological space is
represented by glycogen phosphorylase (GP), the main
regulatory enzyme of glycogen metabolism. GP, catalysing
the rate-determining step of glycogen degradation in the
liver by phosphorolysis, is directly responsible for the
regulation of blood glucose levels. Thus, the enzyme has
become a validated target in combatting non-insulin-
dependent or type 2 diabetes mellitus (NIDDM or T2DM),
and its inhibitors are considered as potential antidiabetic
agents. The biochemical and pharmacological background
of this research has been amply summarized in several
reviews of the past decade, therefore, the reader is kindly
referred to those papers [3–8].
Diverse classes of compounds [4,9–12] can be found
among inhibitors of GP binding to one (or in speciﬁc cases
more) of the so far discovered binding sites of the enzyme
(Fig. 1). The most populated class of compounds is that of
glucose derivatives, ﬁrst proposed and investigated
[4,13,14] by Fleet, Johnson, and Oikonomakos,1 which
bind primarily to the active site of GP. This paper highlights
the most important ‘‘historical’’ moments of GP inhibitor
design among glucose analogues, and themain emphasis is
put on developments of the past couple of years, not or not
fully included in the last comprehensive reviews [11,12].
Although the design of compounds was heavily based on
and supported by results of crystallographic investigations
of enzyme–inhibitor complexes and molecular dockings,
the syntheses and structure–activity relationships of the
inhibitors are pointed out in this overview.
2. Early glucose analogue inhibitors of glycogen
phosphorylase
The weak binding of D-glucose anomers 1 and 2 to the
catalytic site of GP to act as the physiological regulator of
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the enzyme [15] raised the possibility to design glucose
derivatives with much higher afﬁnity to the active site.
Enzymatic tests of a large series of a- and b-D-glucopyr-
anosides, 1-thio-D-glucopyranosides, N-acyl-b-D-gluco-
pyranosylamines and related compounds [13] revealed
1-deoxy-D-gluco-heptulopyranose 2-phosphate (3) and N-
acetyl-b-D-glucopyranosylamine (4) as the ﬁrst glucose
derivatives with an inhibitor constant (Ki) in the low
micromolar range. Anhydro-heptonamides 5 and 6 were
less effective, however, a formal combination of 6 with an
anomeric substituent similar to that of 4 gave again a low
micromolar inhibitor 7. Ring closure of 7 to glucopyr-
anosylidene-spiro-hydantoin 8 strengthened the binding
by a factor of 5. The spiro-epimeric hydantoin 9 proved
much less efﬁcient, indicating that the presence of a b-D-
anomeric NHwas very important tomake a good inhibitor.
This was rationalized by crystallographic investigation of
the enzyme–inhibitor complex [16] to show the presence
of a speciﬁc H-bridge between NH and His377 next to the
catalytic site also present in N-acyl-b-D-glucopyranosyla-
mine type inhibitors (Fig. 2a for an illustration). The
synthetic problems with the stereoselective preparation of
the properly conﬁgured spiro-hydantion 8 [17–19] were
essentially overcome by the highly stereoselective synthe-
sis of spiro-thiohydantoin 10 [20] which proved equipo-
tent with 8 (Fig. 3).
3. Glucose derivatives tested recently as inhibitors of
glycogen phosphorylase
3.1. N-Acyl-b-D-glucopyranosylamines and related
compounds
Following the success of the ﬁrst N-acyl-b-D-glucopy-
ranosylamine type inhibitors like 4, severalmodiﬁcations of
the acyl group were carried out. A widely applied general
method for the preparation of such compounds starts with
the reaction of per-O-acetylated b-D-glucopyranosyl azide
11 with triaryl- or trialkyl phosphanes (PMe3 proved the
most advantageous [27]) and the intermediate phosphini-
mine is then reacted with a carboxylic acid or acid chloride
or anhydride to get protected amides 14 (Scheme 1, for an
exhaustive review see [28]). Reduction of 11 to 15 followed
by acylation can be an alternative synthetic route. Subse-
quentdeprotectionyields test compoundsof type14 (R=H),
and several recent examples as inhibitors of rabbit muscle
GP b (RMGPb) are shown in Fig. 4.
Substitution in the methyl group of N-acetyl-b-D-
glucopyranosylamine makes the inhibition weaker (Fig.
4, compare 4 and 14a,b). The a-anomeric triﬂuoroaceta-
mide 17 proved conﬁgurationally stable (for a discussion
on the stability of N-acyl-glycosylamine anomers see ref.
[27]) but showed no inhibition. From a larger collection of
monoamides of dicarboxylic acids, 14c showed similar
inhibition to that of 4, while its methylester 14d proved
signiﬁcantly weaker. In the series of oxamic acid deriva-
tives, the efﬁciencies of acid 14e and ester 14f were
reversed, both being much less effective than 4. Introduc-
tion of a large side chain as in 14g made a weak inhibitor.
Among aromatic amides, the 2-naphthoyl derivative 14h
proved the most efﬁcient, and in this series, the position
occupied by the aromatic moiety becomes also important
(Fig. 5 also). Necessity of the intact homoaromatic system
is indicated by 1,4-benzodioxane carboxamide 14i. Chan-
ging the acyl part to a dimethoxyphosphoryl residue (18)
resulted in a practical loss of inhibition.
Syntheses of analogues 19 of spiro-hydantoins 8-10
were envisaged by photocyclization of acyl urea deriva-
tives 20 outlined in Scheme 2a. To this end, reported
cyclizations of 3-oxoalkyl glycosides [38,39] 23 resulting
in stereoselective formation of spiro-acetals 24 (Scheme
2b) served as analogies. Thus, a photoexcitation of 20







































































Fig. 1. A schematic diagram of the muscle GPb dimeric molecule viewed
down the molecular dyad. The positions are shown for the catalytic,
allosteric, glycogen storage, the caffeine, the indole site, and the novel
binding site for benzimidazole. The catalytic site, marked by 2-b-D-
glucopyranosyl benzimidazole, is buried at the centre of the subunit and
is accessible to the bulk solvent through a 15 A˚-long channel. Binding of
the competitive inhibitor benzimidazole promotes the less active T state
through stabilization of the closed position of the 280 s loop (shown in
white). The allosteric site, which binds the activator AMP (indicated in the
ﬁgure), is situated at the subunit–subunit interface some 30 A˚ from the
catalytic site. The inhibitor site or caffeine binding site, which binds
purine compounds, such as caffeine and ﬂavopiridol (indicated), is
located on the surface of the enzyme some 12 A˚ from the catalytic site
and, in the T state, obstructs the entrance to the catalytic site tunnel. The
glycogen storage site (with boundmaltopentaose) is on the surface of the
molecule some 30 A˚ from the catalytic site, 40 A˚ from the allosteric site
and 50 A˚ from the new allosteric inhibitor site. The new allosteric or
indole binding site, located inside the central cavity, formed an
association of the two subunits, bound indole-2 carboxamide
analogues, N-benzoyl-N’-b-D-glucopyranosyl urea, and benzimidazole
(indicated). The novel binding site with bound benzimidazole, also
located on the surface of themolecule, is some 31 A˚ from the catalytic site,
32 A˚ from the allosteric site, and 32 A˚ from the indole site (ﬁgure by
courtesy of N.-G. Oikonomakos and E.-D. Chrysina).
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intramolecular hydrogen abstraction to give 21 and
subsequent radical combination could have given the
target compounds 19.
To test this hypothesis, N-acyl-N’-b-D-glucopyranosyl
ureas of type 27 (Scheme 3) were needed. Only two
examples of this class of compounds were known in the
literature [40] which were obtained by a modiﬁcation of
the original synthesis. Azide 11was transformed to urea 26
by Pinte´r et al.’s method [41] and then acylation was
carried out to give 27 (R = Ac, R’ =Me or Ph). Irradiation of
27 under various conditions brought about a Norrish I type
cleavage of the R’COmoieities leading back to 26 instead of
the expected Norrish II type cyclization [42]. Quite
unexpectedly, the deprotected compounds 27 (R = H,
R’ =Me Ki = 305mM; R’ = Ph Ki = 4.6mM) proved efﬁcient
inhibitors of GP [43] and the benzoyl derivative had similar
potency to those of spiro-hydantoins 8 and 10. Initiated by
this serendipitous ﬁnding, synthetic and enzymatic studies
were started to get insight in structure–activity relation-
ships of b-D-glucopyranosyl derivatives attached to
aromatic rings by linkers of 3-6 atoms analogous to amide
groups.
N-Aryl-N’-b-D-glucopyranosyl ureas 13 were obtained
(Scheme 1) either via acid catalysed hydration of
carbodiimide 12 obtained from azide 11 by a Staudinger
type transformation, or by reacting glucosylamine 15with
isocyanates, or by in situ conversion of 15 into glucosy-
lisocyanate 16 [44] followed by amine addition. Removal
of the protecting groups was straightforward under
Zemple´n conditions. Further compounds of the protected
N-acyl-N’-b-D-glucopyranosyl urea series 27 (Scheme 3)
were obtained in reactions of glucosylamine 15 with acyl-
isocyanates or from glucosylisocyanate 16 upon treatment
with arenecarboxamides. During these syntheses, anome-
rization was observed in almost every cases thereby
diminishing the yield of the target compounds [45].
Furthermore, deprotection of acyl ureas 27 was always
accompanied by the cleavage of the R’CO group, both under
base or acid catalysed transesteriﬁcation conditions. These
side reactions could be circumvented by the addition of
unprotected b-D-glucopyranosylamine obtained in situ
from b-D-glucopyranosylammonium carbamate [46] (25)















































































Fig. 2. Outline of binding of glucose analogues at the active site of glycogen phosphorylase (GP) highlighting (a) important H-bonds between N-acyl-b-D-



































































































Fig. 3. Inhibition of glycogen phosphorylase (GP) by D-glucose and the
most efﬁcient inhibitors of early glucose analogue derivatives (Ki [mM]
against RMGPb).
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27 ureas [45]. Biurets 28 [47] and 29 [42] were prepared in
reactions of urea 26 with phenyl and 2-naphthoyl
isocyanates, respectively.
Most important results of the enzyme kinetic studies are
collected in Fig. 5. Comparison of entries 1, 2, 4, 13, and 14
shows that the inhibition is strongest for the acyl urea type
compounds (entry 4). Introduction of a tetrahedral element
into the linkermakesweaker inhibitors (compare entries 2–
3, 4–6). Replacement of one NHCO by a more rigid bond
(entries 4, 7, 9) seems less detrimental, although the
inhibition isweakened, showing thenecessityof apolar part
capable for participation in H-bonds as well. Entries 7 and 8
indicate again that higher ﬂexibility due to a rotatable
element of the linker is not advantageous (of course, the
absence of the H-bond donor amide moiety from the
anomeric carbon must also contribute to the weaker
binding). Constitutional isomers of the NHCONHCO moiety
(entries 10–12) also make signiﬁcantly less efﬁcient
inhibitors. Comparison of columns A–C demonstrate the
importance of the size and orientation of the aromatic
appendage the 2-naphthyl derivatives exhibiting the
strongest binding. Accordingly, N-2-naphthoyl-N’-b-D-glu-
copyranosyl urea (entry 4C)was theﬁrst nanomolar glucose
analogue inhibitor of GP. Protein crystallography showed
acyl ureas of entries 4A and 4C to bind also to the new
allosteric site of the enzyme [43].
X-Ray crystallographic studies of GP–N-acyl-N’-b-D-
glucopyranosyl urea complexes revealed that, contrary to
the N-acyl-b-D-glucopyranosylamines, there is no H-bond
between the b-anomeric NH and His377 (Fig. 2b) [43]. As
the acyl ureas are much more inhibitory than the
corresponding glucosylamines (Fig. 5, entries 1 and 4),
the stronger binding must be due to extended interactions
of the urea and especially the aromatic parts of the
molecules in the b-channel2 of the enzyme. This observa-
tion was utilized in further inhibitor design discussed in
Section 3.4.
Very recently, a new series of aldehyde 4-(b-D-
glucopyranosyl)-thiosemicarbazones [52,53] was pre-
pared from per-O-acetylated b-D-glucopyranosylisothio-
cyanate (Fig. 6) and several of them showed micromolar
inhibition.
3.2. N-b-D-glucopyranosyl heterocycles
The problems encountered in the synthesis ofN-acyl-b-
D-glucopyranosyl ureas necessitated a quest for more



























































































X = OH, Cl,




























































Fig. 4. Inhibition of rabbit muscle glycogen phosphorylase b (RMGPb) by
N-acyl-b-D-glucopyranosylamines and related compounds. Illustrative
examples of the most efﬁcient members of larger series of compounds
detailed in the referred papers.
2 Theb-channel orb-pocket is an empty space next to the catalytic site
of GP in the direction of the b-anomeric substituent of bound D-glucose
surrounded by amino acid side chains of mixed character.
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NHCO moieties in acyl ureas and related compounds was
envisaged. As the ﬁrst example of such studies, the NHCO
unit of N-acyl-b-D-glucopyranosylamines was changed to
1,2,3-triazole because some literature examples indicated
similarities [56] of these two moieties. Three series of 1-D-
glucopyranosyl-4-substituted-1,2,3-triazoles [51] were
prepared by copper(I) catalysed azide-alkyne cycloaddi-
tion (CuAAC) [57] outlined in Scheme 4. From b-D-
glucopyranosyl azide 11 conditions 1a, frequently applied
in the literature, proved to be a straightforward way to the
per-O-acetylated 1-b-D-glucopyranosyl-4-substituted-





























2. NHCONH 1848 35048 (IC50) 5.248
3. NHCOCH2 1100 (IC50) 34 - -
4. NHCONHCO 4.6 43 1042 0.3542
5. NHCONHCH2 42 % (1 mM) 48 - -
6. NHCOCH2CH2 8534 - -
7. NHCOCH=CH 1834 - 3.534
8. CH2COCH=CH - - 52 % (100 μM)49*
9. NHCOC≡C 6234 - -
10. NHCOCONH 10050 14450 5650
11. CONHCONH No inh.48 - -
12. CONHNHCO 22 % (3.75 mM)50 - -
13. NHCONHCONH 2147 - -









Fig. 5. Comparison of inhibition of rabbit muscle glycogen phosphorylase b (RMGPb) (Ki [mM]) by N-acyl-b-D-glucopyranosylamines, N-substituted-N’-b-
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a-azide 30 required higher catalyst loads (conditions 1b)
and the yields for the corresponding per-O-acetylated 1-a-
D-glucopyranosyl-4-substituted-1,2,3-triazoles were low-
er (36–72%). The aqueous conditions were unsatisfactory
for the reactions of (hept-2-ulopyranosylazide)onamide 31
forwhich conditions 1cwere found the best to give 75–87%
of the corresponding O-protected glucosyl triazoles with
51–73% conversion of the starting 31 in one day. Removal
of the protecting groups was effected by the Zemple´n
protocol to give triazoles 32-34 in generally very good
yields.
From these 1,2,3-triazoles, only compounds 32 showed
signiﬁcant inhibition (e.g. R = CH2OH Ki = 26mM [51] or
14mM; [35]). Inhibitor constants for othermembers of this
series can be found in Fig. 5, entry 15 to show acceptable
similarity with those of glucosyl amides in entry 1.
Comparative crystallographic studies of the amide and
triazole series revealed that pairs of the compounds with
the same aglycon bound to the enzyme in essentially the
same way in most cases [35]. Thereby, the bioisosteric
relationship for NHCO-1,2,3-triazolewas proven for the GP
case as well.
Investigations of some N-b-D-glucopyranosyl deriva-
tives of pyrimidine and purine heterocycles (‘‘glucosyl
nucleosides’’) showed these compounds to have inhibitory
effect towards GP, and the best inhibitors are collected in
Fig. 7.
3.3. C-b-D-glucopyranosyl derivatives
The ﬁrst C-b-D-glucopyranosyl heterocycles tested as
inhibitors of GP were methyl-1,3,4-oxadiazole 38, tetra-
zole 39, benzothiazole 40, and benzimidazole 41 (Scheme
5, R = H in each) [59]. Common starting material for the
syntheses of these compoundswas the per-O-acetylated or
-benzoylated 2,6-anhydro-aldononitrile (b-D-glucopyra-
nosyl cyanide) 36. 1,3-dipolar cycloaddition of protected
36 with azide ion gave 5-b-D-glucopyranosyl tetrazole 39
which was transformed into 2-b-D-glucopyranosyl-5-





















































































hν in MeOH or PhH











































































R = Ac H







NO2 8 % (at 625 μM)
54
Me 10155
Fig. 6. Synthesis of aldehyde 4-(b-D-glucopyranosyl)thiosemicarbazones and their enzymatic evaluation against rabbit muscle glycogen phosphorylase b
(RMGPb).
L. Somsa´k / C. R. Chimie xxx (2010) xxx–xxx6
G Model
CRAS2C 3372 1–13
Please cite this article in press as: Somsa´k, L., Glucose derived inhibitors of glycogen phosphorylase. C. R. Chimie (2010),
doi:10.1016/j.crci.2010.09.004
intermediate obtained by acylation of 39 [59,60]. Oxadia-
zoles 38 could also be prepared by oxidation [60] of 2,6-
anhydro-aldose acylhydrazones [61] 35, and the two
pathways proved comparable with respect of yields and
operational difﬁculties. Nitrile 36 was ring-closed to
benzothiazole 40 with 2-aminothiophenol. The analogous
reaction with 1,2-diaminobenzene was unsuccessful,
therefore, benzimidazole 41 was obtained via thioimidate
37. Deprotection was carried out by the Zemple´n method.
Per-O-benzoylated or -benzylated nitriles 36 were also
transformed into two other series of 1,2,4-oxadiazoles
(Scheme 6). 1,3-dipolar cycloaddition with nitrile-oxides
generated in situ furnished 5-b-D-glucopyranosyl-3-
substituted-1,2,4-oxadiazoles 43 [60,62]. Addition of
hydroxylamine to 36 produced amidoxime 42which upon
O-acylation with either carboxylic acids or acid chlorides
followed by cyclodehydration gave 3-b-D-glucopyranosyl-
5-substituted-1,2,4-oxadiazoles 44 [63]. The protecting
groups were removed by standard methods.
Results of enzyme kinetic studies are presented in Fig. 8.
b-D-glucopyranosyl cyanide 36 is a somewhat better
inhibitor than anhydro-aldonamide 5, while tetrazole 39
and amidoxime 42 are inactive. Benzimidazole 41 binds
stronger thanbenzothiazole40, and this canbeattributed to
the H-bond between the NH of the heterocycle and His377
which isnecessarily absent for40. X-ray crystallographyhas
shown41also tobepresent at thenewallosteric site and the
new ‘‘benzimidazole site’’ has been discovered by investi-
gating this compound (Fig. 1) [64]. From the three
oxadiazole series (38, 43, 44), compounds 43 are the most














































































R = CH2OH, COOEt(Me), Ph, 1-naphthyl, 2-naphthyl
1. R-C CH  [1 eq in a) and b); 2 eq in c]
a) 0.015 eq CuSO4, 0.2 eq L-ascorbic acid, water, 70 °C
b) 0.075 eq CuSO4, 0.2 eq L-ascorbic acid, water, 70 °C
c) 0.11 eq CuSO4, 0.3 eq L-ascorbic acid, DMSO, 70 °C


















Fig. 7. Inhibitory effect of b-D- glucopyranosyl nucleosides against rabbit














































40 X = S
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large and properly oriented aromatic substituent can be
observed in the oxadiazoles, too: compounds with a 2-
naphthyl appendage (43d, 44d) are the best inhibitors.
Although all three oxadiazoles could be considered as
bioisosteric replacements [65,66] of NHCO, these results
suggest that in the case of GP, 5-b-D-glucopyranosyl-3-
substituted-1,2,4-oxadiazoles 43 are the best choice.
b-D-glucopyranosyl hydroquinone derivative 46 in its
O-acetyl protected form was prepared by aromatic
electrophilic substitution in 1,4-dimethoxybenze using
penta-O-acetyl-b-D-glucopyranose as a source of glucosy-
lium ion. Subsequent oxidation gave protected benzoqui-
none 47 which was reduced to 45 [67]. The deprotected
compounds were moderately inhibitory against GP (Fig.
9). Cyclopropane 48was obtained from per-O-benzoylated
nitrile 36 by EtMgBr–Ti(OiPr)4 followed by Zemple´n
deprotection [68]. This compound had no inhibition of GP.
3.4. Glucopyranosylidene-spiro-heterocycles
Studies on N-acyl-b-D-glucopyranosylamines and N-
acyl-N’-b-D-glucopyranosyl ureas allowed to conclude that
it is possible to make very efﬁcient inhibitors even in the
absence of a H-bond to His377, provided that interactions
in the b-channel are strong enough. Combining these facts
with the spirobicyclic structure of hydantoins, a novel
design principle for efﬁcient glucose-based inhibitors of GP

































































































5 R = CONH2 44024
36 R = CN 13059
42 R = C(=NOH)NH2 No inh.63
39 No inh.59
40 X = S 
22959
7664




























-- 44a No inh.63




44b 10 % 
(625 ?M)63
38c 10 % 
(625 μM)60 43c 19
60 44c No inh.63
38d 10 % 
(625 μM)60 43d 2.4
60 44d 3863








45 R = H  
90067


















O 48 No inh.
(625 μM)68
Fig. 9. b-D-Glucopyranosyl carbocycles as inhibitors of rabbit muscle
glycogen phosphorylase b (RMGPb) (Ki [mM]).
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 such molecules should have a rigid spirobicyclic scaffold
in which a (preferably ﬁve-membered hetero) cycle is
attached to the anomeric carbon of D-glucopyranose;
 this cycle, although itmay, should not necessarily be a H-
bond donor towards His 377;
 a suitably oriented, large aromatic appendage must be
present on this cycle to ﬁt into the b-channel.
This principle was ﬁrst veriﬁed by spiro-oxathiazolines
53, the synthesis of which followed well elaborated
pathways [71] (Scheme 7): per-O-acetylated 1-thio-b-D-
glucopyranose 49 was reacted with in situ generated
nitrile-oxides to give hydroximothioates 50 which under-
went a ring-closure upon oxidation by NBS to yield the
target compounds 53 after Zemple´n deprotection. Synthe-
sis of the analogous spiro-oxadiazoline 54 was also
attempted. To this end, glucosyl azide 11was transformed
in a Staudinger type reaction into N-b-D-glucopyranosyl
amidoxime 51. Oxidative treatment of 51 gave oxadiazole
52 probably via 54. The driving force for the tautomeric
ring opening must be the aromatization of the heterocycle.
A series of glucopyranosylidene-spiro-isoxazolines 58
was prepared by 1,3-dipolar cycloaddition of nitrile-oxides
to exo-glycals 57 (Scheme 8) [62]. The exomethylene
sugars were made by Julia oleﬁnation of per-O-benzylated
or -silylated lactone 55. Protecting group exchange to get
the per-O-acetylated 57 was necessary because upon
hydrogenolytic debenzylation of 58, the isoxazoline ring
also opened up due to a cleavage of the N–O bond. O-
deacetylation of 58 could be achieved by the Zemple´n
protocol. Another way to 57was reported by transforming


































































53c 8.2 58c 6.6
53d 0.16 58d 0.63



































R = Ac, Bz, Bn, Et3Si  







































 53 X = S









50 X = S from 49
51 X = NH from 11
52













       reflux
        1. PMe3 in 
        PhMe-CH2Cl2
2. R'C(Cl)=NOH
Scheme 7.
L. Somsa´k / C. R. Chimie xxx (2010) xxx–xxx 9
G Model
CRAS2C 3372 1–13
Please cite this article in press as: Somsa´k, L., Glucose derived inhibitors of glycogen phosphorylase. C. R. Chimie (2010),
doi:10.1016/j.crci.2010.09.004
drazones followed by a Bamford-Stevens type carbene
generation to yield the target exo-glycals [72,73].
Enzyme kinetic investigation of these spirocycles (Fig.
10) indicated low micromolar inhibition of GP by the
phenyl substituted derivatives 53a and 58a. Substitution
in the para-position of the aromatic ring gave somewhat
better inhibitors (53c, 58b,c). The 2-naphthyl derivatives
(53d, 58d) were nanomolar inhibitors, thereby fully
validating the design principles.
3.5. Miscellaneous compounds
Several O-, S-, and N-glucosides (Fig. 11, 59-63) of b-D-
gluco-hept-2-ulopyranosonamide were prepared by nu-
cleophilic substitutions of the corresponding glycosyl
bromide [75]. These compounds can be regarded as
anomerically extended variants of amide 6 for which a
b-anomeric carbamate moiety (7) signiﬁcantly improved
the inhibitory efﬁciency. On the other hand, the new
substitution patterns of 59-63 weakened the inhibition.
Sulfonamide 64 prepared recently by two different
methods [76,77] had no inhibition against RMGPb.
Very recently,multivalentmoleculeshavebeendesigned
and proposed for inhibition of GP [79]. Compound 65 (Fig.
12) was prepared by acylation of amidoxime 42 with
trimesic acid chloride. To get compound 67 containing a
spacer, 42 was acylated with 4-pentynoic acid followed by
CuAAC with 1,3,5-tris(azidomethyl)benzene. These com-






















































44b R’ = H      
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68 n = 1, 5, 10, 15 No inhibition of RMGPb at 625 μM















Oleanolic acid (OA) R1 = H, R2 = H, R3 = CH3
Ursolic acid (UA) R1 = H, R2 = CH3, R3 = H
Maslinic acid (MA) R1 = OH, R2 = H, R3 = CH3
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Acid R n
a OA Ac - 337
b OA H - 26
c UA Ac - 51
d UA H - 45
e MA Ac - no inh.

















a OA Ac 1 68
b UA Ac 10 65
c MA Ac 1 78











59 OEt 21 % (at 625 μM)75
60 SPh No inh. (at 625 μM)75








SO2NH2 No inh. (at 625 μM)76
64
Fig. 11. Inhibition of rabbitmuscle glycogen phosphorylase b (RMGPb) by
various monosaccharide derivatives.
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bind to an active site of GP. It was found that the
homotrivalent derivatives 65 and 67 had slightly better
inhibitory activity than the corresponding monovalent
compounds 44b and 66, respectively. Homobivalent
compounds 68 were made by CuAAC from N-v-azidoal-
kanoyl-b-D-glucopyranosylamines and 1,7-octadiyne, but
had no effect on the enzyme [80].
Potentially heterobivalent compounds were designed
by tethering pentacyclic triterpenes and D-glucose deri-
vatives [80]: C-28 propargyl esters of oleanolic, ursolic, or
maslinic acids were coupled by CuAAC with b-D-glucopyr-
anosyl azide and N-v-azidoalkanoyl-b-D-glucopyranosy-
lamines to give compounds 69 and 70, respectively.
Derivatives with both per-O-acetylated and unprotected
sugar parts were tested against GP and the best inhibitors
are shown in Fig. 12. Micromolar inhibitors could be
identiﬁed among both protected and unprotected glucose
derivatives, and also the triterpene part and, in some cases,
the linker length had a bearing on the efﬁciency of the
compounds.
Oleanolic acid and D-glucose were also conjugated via
C-6 ethers and glucuronic esters in several ways [81]. Most
efﬁcient compounds are 71b and 72a (Fig. 13) interest-
ingly with an unprotected and a protected sugar unit,
respectively. Based on molecular docking, 71b was
proposed to bind at the allosteric site of GP. Per-O-
benzylated precursor sugars 73 and 74 containing a
propargyl group also exhibited inhibition of GP, the latter
in the low micromolar range.
4. Conclusion
Extensive synthetic efforts supported by crystallo-
graphic studies on enzyme–inhibitor complexes have
resulted in several new types of glucose analogue
inhibitors of GP. Among them, N-acyl-N’-b-D-glucopy-
ranosyl ureas, glucopyranosylidene-spiro-oxathiazolines
and -isoxazolines represent novel scaffolds which, in the
presence of suitable substituents, exhibit nanomolar
efﬁciency. Further increase in the binding strength of
glucose analogues may be expected from a better
exploitation of interactions of the molecules in the b-
channel of the enzyme. This will need a strong collabora-
tion between synthetic and computational chemists, as
well as crystallographers and biochemists. Nevertheless,
due to the extremely high ﬂexibility of the catalytic site of
GP, synthesis and enzyme kinetic study of a large number
of compounds will be inevitable.
5. Note added in proof
While this manuscript was under review, an interesting
paper appeared on enzyme kinetic and crystallographic
investigations of a series of 3-deoxy-3-ﬂuoro-b-D-gluco-
pyranosyl pyrimidine derivatives [82].
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